arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Prime Medicine, Inc.

PRME

$3.08 ▲ +0.15 (+5.13%) at close

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Prime Medicine, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $458.2M

Dividend Yield —

Revenue Growth 55.3%

Op. Margin None

ROIC -136.2% ↘

FCF / Share $-1.12 ↘

Trailing P/E —

Price / Book 4.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$4.63M

↑ +55.3% —

Net Income Profit after all expenses

$-201.14M

↓ -2.7% —

FCF / Share Free cash flow per share

$-1.12

↓ -2.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	55.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+591%)	—	—	—	N/M	—	—
EPS Growth YoY (%)	18.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	24.3% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	48.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	70.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-642.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-2.7% Weak ↑ Weak Improving Year-over-year change in net income	1.1% Caution ↑ Caution Improving Year-over-year change in net income	-62.6% Weak ↑ Weak Improving Year-over-year change in net income	26.3% Excellent Excellent Year-over-year change in net income	-4749.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-2.4% Weak ↓ Weak Declining Year-over-year change in free cash flow	42.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	56.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-48.1% Weak Weak Year-over-year change in free cash flow	-25.8% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 5Y (%)	-2.3% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-17.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-219%)	—
Profit Margin (%) (%)	—	—	—	—	—	-65.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-645%)	—
FCF Margin (%) (%)	—	—	—	—	—	-118.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.81x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-136.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-104.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-121.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	42.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-31.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-60.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-68.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-105.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-28.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-166.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1209%)	-127.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-953%)	-148.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1093%)	-38.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-357%)	105.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+606%)	-145.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1072%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-63.03M	$-182.48M	$-41.57M	$-187.62M	$-185.42M	$-36.98M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.03	$0.03	$0.00	$0.00	$0.00	$1.97	—
Basic EPS, GAAP (USD)	$-1.35	$-1.65	$-2.18	$-4.19	$-14.19	$-1.91	—
Free Cash Flow per Share (USD)	$-1.12	$-1.10	$-1.91	$-4.36	$-2.95	$-2.34	—
Book Value per Share (USD)	$0.67	$1.17	$1.37	$3.25	$-4.82	$0.89	—
Tangible Book Value per Share (USD)	$0.67	$1.17	$1.37	$3.25	$-4.82	$0.89	—
Basic Weighted Avg Shares (shares)	148.76M	118.60M	90.97M	33.89M	12.97M	2.64M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$143.84M	$173.93M	$86.55M	$269.90M	$212.60M	—	—
Total Equity (USD)	$120.87M	$153.15M	$133.07M	$316.27M	$-156.24M	$2.34M	$-2.60M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$4.63M	$2.98M	$0.00	$0.00	$0.00	$5.21M	—
Depreciation Expense (USD)	$7.32M	$6.13M	$4.65M	$2.22M	$568.00K	$43.00K	—
Net Income, GAAP (USD)	$-201.14M	$-195.88M	$-198.13M	$-121.82M	$-165.37M	$-3.41M	—
Operating Cash Flow (USD)	$-162.56M	$-122.86M	$-165.41M	$-131.83M	$-34.08M	$-5.54M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters

Prime Medicine, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PRME with peers